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ABSTRACT 
Antibody to Tamm-Horsfall protein (THP) was measured using a radio¬ 
immunoassay in 45 patients on chronic hemodialysis. Of these 45 patients, 
13 had renal failure secondary to polycystic kidney disease, 14 had failure 
secondary to glomerular diseases, nine had failure secondary to diabetes, 
three had failure secondary to interstitial nephritis, three had failure sec¬ 
ondary to chronic pyelonephritis, two had failure secondary to multiple 
myeloma, and one had failure secondary to urinary tract obstruction. Re¬ 
sults from these 45 patients were compared to levels of antibody measured 
in sera from 10 healthy controls. In no group was the mean titer signifi¬ 
cantly different from the mean of the control group. Four patients had 
significantly elevated titers of antibody but there were no correlating 
features among them. 
Observations during the study revealed that heparinized samples of 
blood, following cell removal, had lower titers of antibody to THP than 
did non-heparinized samples from the same patient. Further investigation of 
this finding, using other anticoagulants, lead to the suggestion that 
clotting factors were the cause of the observed interference. 

INTRODUCTION 
Since its discovery and characterization by Tamm and Horsfall (1) 
the importance of the 80,000 molecular weight glycoprotein which carries 
their name remains a mystery. Only the cells lining the ascending loop 
of Henle and distal convoluted tubule synthesize the protein, which is 
secreted into the tubular lumen (2,3). No physiological role for the 
protein is known although the original investigators noted it inhibited 
hemagglutination caused by influenza, mumps and Newcastle disease virus (1), 
but had no effect on bacteria (4). Approximately 50 mg of Tamm-Horsfall 
protein (THP) is excreted per day in human urine, and in the presence of 
low pH or high salt concentration in the urine, the protein aggregates and 
forms casts (4-6). 
Recent work implicates THP in various pathological processes affecting 
the kidney, including calculi formation (7), and other precipitates which 
may be a factor in the pathogenesis of acute renal failure by causing micro¬ 
scopic tubular obstruction (8). 
In addition, THP and the immunologic response induced by it are 
implicated in many interstitial diseases of the kidney. Rats immunized to 
homologous THP develop tubulo-interstitial nephritis (9). In humans, antibody 
to THP has been described in patients with reflux nephropathy (10), with 
urinary tract obstruction (UTO) and urinary tract infection (UTI) (11), and 
pyelonephritis (12). Intrarenal deposits of THP have been described in 
medullary cystic disease (13), chronic pyelonephritis, and hydronephrosis 
with suggestions that THP may be involved in the pathogenesis of these 
diseases (13,14). 
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One theory which explains the potentially pathogenic role of THP 
suggests that THP is normally not seen by the immune system and that with 
obstruction or reflux, urine containing THP flows retrograde into renal 
parenchymal lymphatics and veins (10,15,16), thus rendering this sequestered 
protein immunogenic. Indeed, urine does reflux into lymphatics and renal 
veins in patients with UTO and vesico-ureteral reflux (VUR) (17,18). Also, 
tubulo-interstitial nephritis has been produced in animals immunized with 
THP (9). 
If this same process of immunization occurs in man, patients with VUR 
or UTO might become immunized to their own THP and a useful marker of 
early disease would be titers of the induced anti-THP antibody. Conceivably 
these titers would be elevated before irreversible renal damage occurred 
and would provide a simple, non-invasive method for detection of early 
disease. Recent work in this laboratory (11) showed significant elevations 
of THP antibody in 5/15 patients with UTO and UTI when compared to healthy 
controls. Others have shown elevated titers of antibody in school age girls 
with symptomatic "upper" UTI (12). However, there is no evidence for the 
presence of anti-THP antibody in patients with later or end-stage kidney 
disease. 
The natural history of VUR can be insidious. In one study (19) some 
patients had VUR undiagnosed until renal failure occurred. These patients 
had parenchymal changes in their kidneys which were characteristic of chronic 
pyelonephritis (CPN). Others have shown that severe VUR plus UTI lead to 
renal scarring and fibrosis (20). 
Since VUR and UTO can lead to CPN and end-stage renal disease, and since 
increased anti-THP antibody have been demonstrated in school age girls with 
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acute pyelonephritis (12) and in patients with UTO and infection (11), it 
seemed important to determine anti-THP antibody titers in patients with CPN, 
UTO and interstitial nephritis (IN). This might help to define the role, 
if any, of THP antibody in the pathogenesis of these diseases. 
The current study evaluates patients with end-stage renal disease on 
maintenance hemodialysis, with diagnoses of UTO, IN, and CPN, and compares 
them with patients with other causes of end-stage renal disease including 
polycystic kidney disease (PCKD), glomerulonephritis (GN), and diabetic 
nephropathy (DN), as well as healthy control subjects. 
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METHODS 
Patient Selection 
A total of 45 chronic hemodialysis patients at Yale-New Haven Hospital 
and the West Haven Veterans Administration Hospital participated in this 
study after giving informed consent. All of these patients had a diagnosis 
for their renal failure based on clinical, radiological or histological 
evidence. This information, along with information about UTI, current and 
past medications and length of time on dialysis, was obtained from the 
patient’s hospital record. 
Patients were placed into groups based upon the etiology of their renal 
failure. These groups included: (1) Thirteen patients with PCKD where the 
diagnosis was made by intravenous pyelography or laparotomy. (2) Nine patients 
with DN, diagnosis made on clinical evidence of diabetes mellitus and sequellae 
including cataracts and retinopathy in eight of nine, and one patient with 
history of diabetes and a biopsy which showed interstitial nephritis. (3) 
Fourteen patients with glomerulonephritis (GN), eleven of fourteen had biopsies, 
showing membranoproliferative GN in three, membranous GN in two, chronic 
progressive hypo-complementemic GN in one, and chronic GN (CGN) in five. In 
the remaining three patients without biopsy, the diagnosis of CGN was based on 
a history of acute GN which progressed to renal failure in one, a history of 
beta hemolytic streptococcal infection followed by hematuria, albuminuria, 
and progressive renal failure in another, and a history of skin infections 
leading to progressive renal failure in the third. (4) Six patients with the 
diagnosis of CPN or INr whose diagnoses were based on a history of phenacetin 
abuse in one, neomycin induced deafness and renal failure in one, biopsy in two, 
and by renal scan and pyelography in the other two. (5) One patient with 
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UTO diagnosed with IVP, and (6) two patients with multiple myeloma(secretory 
type) who developed renal failure with progression of their disease. 
Blood Collection 
Blood was obtained from each patient for determination of anti-THP 
antibody titers. In order to evaluate the effect of dialysis on titers of 
anti-THP antibody, 5 ml samples of blood were obtained from participants 
pre- and post dialysis for later comparison. The samples from Yale-New 
Haven Hospital were collected in plain vacutainers and allowed to clot at 
room temperature for one hour before serum was removed. The samples from 
the West Haven Veterans Administration Hospital were collected in heparinized 
vacutainers (approximately 120U Hep) and the plasma removed immediately. 
Sodium azide was added to each specimen for bacteriostasis. 
All patients received heparin during dialysis, an initial bolus of 
5000 U followed by three hourly 1000 U doses until dialysis ended after four 
hours. Heparin antagonists were not given to any of the patients. 
Urine 
Clean catch urine specimens were obtained for culture from all patients 
who were not anuric. Quantitative urine cultures were performed by the 
standard pour plate technique. Bacteria recovered were identified by the 
scheme of Schaub and Foley (21). 
THP Antibody 
Serum antibody titers to THP were determined by a radioimmunoassay 
initially developed in this laboratory and described in detail in previous 
publications (11,22). The assay depends on binding specific antibody to a 
solid phase antigen (THP adsorbed to a microtiter plate). The subsequent 
-5- 

125 identification of bound antibody was achieved by adding I labeled Protein 
A which binds to the Fc region of IgG. 
Serial dilutions of rabbit sera containing known amounts of specific 
antibody were assayed simultaneously with the patient samples to obtain a 
standard curve for conversion of counts per minute to ng antibody/ml. 
Heparin Effect 
Preliminary results indicated that the heparinized samples gave consistently 
lower anti-THP titers than unheparinized samples. Further studies were done 
to elucidate the effect of heparin on the assay. 
Heparinized and non-heparinized samples from medical student "volunteers" 
were obtained to evaluate the effect of heparin on freshly collected samples. 
The non-heparinized samples were allowed to clot for one hour and the serum was 
then removed. The heparinized samples were immediately centrifuged and 
plasma removed. All samples received sodium azide as a preservative. 
To evaluate the effect heparin might have directly on antigen-antibody 
binding in the assay, heparin was added to serum from a rabbit immunized to 
human THP in amounts approximately equal to 5x, lOx, 50x, and lOOx the 
calculated concentration of heparin in patients' serum immediately following 
dialysis. The amount of heparin added was calculated by approximating the 
heparin T ^ in serum at 60 minutes (23) for the amounts used. Samples 
containing rabbit serum and heparin were then evaluated for anti-THP activity 
and compared to serum from the same rabbit which received no heparin. 
In order to determine whether heparin exerted a specific effect, or if 
the inhibition observed was a result of some other plasma component, i.e. 
fibrinogen, blood samples anticoagulated with EDTA and Na citrate were 
compared to samples which were heparinized and samples which were not anti¬ 
coagulated. Four samples of blood were taken from each of ten volunteers; 
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one sample without anticoagulent, one with heparin, one with EDTA, and one 
with Na citrate. As a further study to evaluate the effect of fibrinogen 
on the assay, samples collected with EDTA and citrate were defribinated 
by adding back CaCl2- This was done by incubating samples and CaCl2 (final 
0 9 
concentration in samples 0.025M) for one hour at 37 C and then at 4 C for 
twelve hours (24 ). The resulting clot was removed and the samples assayed. 
Statistical Methods 
Patients with antibody titers greater than the mean level of healthy 
control subjects plus two standard deviations were defined as significantly 
elevated titers. Independent groups were compared using T-statistics 
for independent data, heparin vs. serum comparisons were made using the 
paired T test. 
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RESULTS 
Patients with End-Stage Kidney Disease 
Figure 1 displays the antibody titer of patients grouped by diagnosis 
and includes controls. The mean anti-THP antibody titer in ten control subjects 
was 1050 ng/ml and the mean plus two standard deviations was 1920 ng/ml. 
Any titer above this value was considered significant. Sera from the thirteen 
patients with PCKD gave a mean anti-THP antibody titer of 710 ng/ml ± 201 
ng/ml with no values above the level of significance. The mean value of 
anti-THP antibody in sera from fourteen patients with GN was 1190 ng/ml ± 
1040 ng/ml which included two patients with significantly elevated titers 
of 5130 ng/ml and 4440 ng/ml. Sera from nine patients with DN gave a mean 
titer of 1260 ng/ml ± 740 ng/ml and included one patient with a titer of 
4330 ng/ml. Sera from the three patients with CPN gave a mean of 1480 ng/ml ± 
976 ng/ml and none were elevated above normal values. Sera from the three 
patients with IN gave a mean of 1580 ng/ml ± 290 ng/ml including a significant 
titer in one patient, 2050 ng/ml. Sera from the two patients with multiple 
myeloma gave a mean titer of 340 ng/ml and were the lowest for any single 
diagnostic group. The serum from the one patient with UTO gave a titer of 
1090 ng/ml. 
The mean values for anti-THP antibody for each of the groups were not 
significantly different from mean values for healthy subjects. The highest 
mean 1580 ng/ml was seen in patients with IN, followed by CPN 1480 ng/ml, 
DN 1260 ng/ml, GN 1190 ng/ml, UTO 1090 ng/ml, PCKD 710 ng/ml, and MM 340 ng/ml. 
Evaluation of urine culture results from each patient revealed a total 
of twelve patients with significant levels of urinary bacteria. Sera from 
the four patients infected with E. coli had a mean titer of 1640 ng/ml ± 1280 
ng/ml. Sera from the eight other patients with infected urine had a mean 
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anti-THP antibody titer of 876 ng/ml ± 257 ng/ml. Sera from the eleven 
patients with sterile urine had a mean of 850 ng/ml ± 376 ng/ml and the 
twenty-two patients who were anuric had a mean titer of 1180 ng/ml ±775 
ng/ml. Individual results appear in Figure 2. None of the groups were 
significantly different from the control group. Of the four patients with 
significantly elevated titers, one had an E. coli UTI and the other three 
were anuric. 
Figure 3 presents each patient's serum titer of anti-THP antibody as a 
function of the number of months he/she had been on dialysis at the time of 
the study. Figures 4-7 show the same function for each diagnostic group. 
Figure 4 PCKD, Figure 5 DN, Figure 6 GN, Figure 7 CPN and IN. Of patients 
dialyzed twenty months or less, 1/11 had significantly elevated titers. Of 
patients dialyzed between twenty and forty months, 3/14 had elevated titers. 
None of the other nineteen patients had elevated titers. For each group 
there is no trend except for CPN-IN, which suggests a downward trend in 
activity. 
Heparin vs. Non-Heparin 
Pre-dialysis samples (non-heparinized at Yale-New Haven Hospital, 
heparinized at the West Haven Veterans Administration Hospital) and post¬ 
dialysis samples (heparinized during dialysis at both hospitals) were compared 
by hospital. There is a suggestion of significant difference between means 
of pre- (1237 ng/ml) and post- (1081 ng/ml) samples at Yale-New Haven Hospital 
(p=.03) while there is no significant difference between pre- (637 ng/ml) 
and post- (666 ng/ml) samples at the West Haven Veterans Administration Hospital 
(p = 0.64). 
Figure 8 presents results of serum and plasma anti-THP titers in ten 
volunteers expressed in cpm. Each volunteer gave two samples of blood, one 
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heparinized and one not heparinized. The mean antibody titer for non- 
heparinized samples was 7530 cpm ± 4040 cpm and the mean antibody titer in 
heparinized samples was 5600 cpm ± 2780 cpm. These means are significantly 
different (p= 0.003). 
Rabbit Serum 
Figure 9 shows results of adding heparin to rabbit serum, making a 
final heparin concentration of 5x - lOOx the concentration of heparin in 
patients at the end of dialysis. Anti-THP activity remains the same regardless 
of heparin concentration. 
Other Anti-Coagulants 
The results of adding anti-coagulants to freshly drawn samples are 
presented in Table III. Ten volunteers contributed four samples each. There 
is a significant difference between control sera and sodium citrate (p=0.003), 
EDTA (p=0.004), and heparin (p=0.01). No significant difference between 
control and control + calcium (p=0.1), citrate + calcium (p=0.02), and EDTA + 
calcium (p=0.2). However, there is a significant difference between control 
and heparin + calcium (p=0.01). 
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DISCUSSION 
The objective in these studies was to determine if a new assay which 
detects small amounts of anti-THP antibody (500 ng/ml) (11) in healthy 
patients, might detect elevated titers of antibody in patients with various 
forms of end-stage kidney disease. A working hypothesis for this study 
suggested that titers would be elevated in patients with UTO, CPN, or IN, 
because anti-THP might be involved in the pathogenisis of these diseases. 
Although the present work indicates that none of the groups studied had 
mean titers significantly different from controls, it is interesting that 
the group of patients with CPN and IN had the highest anti-THP antibody 
titers. 
Although no general trend is apparent for decreasing amounts of anti-THP 
as a function of number of months on dialysis, it is possible that disease in 
these patients is quiescent, with decreased amounts of antigen available for 
immune reaction, and subsequently decreased immune response and measurable 
antibody. 
Previous attempts to identify antibody to kidney tissue in patients 
with pyelonephritis and chronic nephritis using complement fixation (25), 
latex agglutination (26), and hemagglutination (27), have been unsuccessful. 
However, those assays were less sensitive than the present one and they could 
not identify circulating antibody in normal controls. Using this assay, 
Marier et al (11) demonstrated anti-THP in normal controls and significantly 
elevated titers in patients with VUR and UTI. Hanson (12) also observed 
elevated anti-THP titers in 9/10 school girls with upper UTI using an enzyme 
linked immuno-absorbant assay. 
In the present study, four of the forty-five patients studied had sig¬ 
nificantly elevated antibody titers, but they did not share any other unifying 
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characteristic. Two patients with GN had elevated titers, one of whom also 
had an E. coli UTI. One patient with DN had elevated titers and was anuric, 
and another anuric patient with elevated titers had kidney failure based 
on long standing IN. 
Several hypotheses exist to explain previously observed (11,12) elevated 
anti-THP antibody titers in patients with kidney disease. One hypothesis 
suggests the presence of common immunological determinants shared by bac¬ 
teria and normal kidney tissue so that infection with one of these bacterial 
types leads to an immune response to the invading bacteria and also to the 
shared determinant in normal kidney tissue. If these kidney determinants 
were on tubular cells, then pyelonephritis might occur as a result of immuno¬ 
logic injury. Holmgren et al (28) using immunodiffusion techniques have shown 
that there are common determinants between normal kidney tissue and certain 
strains of E. co3i. Further evidence supporting this hypothesis is presented 
by Kalmanson and Guze (29) who observed that healthy rats parabiosed to rats 
recovering from E. coli pyelonephritis developed histologic evidence of in¬ 
terstitial nephritis which resembled chronic pyelonephritis. This experiment 
does not prove the theory of shared determinants because infectious damage 
to the tubules might release kidney tubule antigen which in turn might be 
recognized as foreign, thus propagating a second and separate immune response. 
These observations suggest a second hypothesis: tubular injury of any 
type leads to release of antigen, with a subsequent, secondary immune 
reaction involving kidney determinants (30). A third mechanism by which 
normal kidney proteins might be recognized as foreien following UTI is 
similar to the mechanism by which methicillin associated interstitial 
nephritis occurs (31) , where methicillin is immunogenic when combined with 
a tubular protein leading to an immune response to both the protein and 
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the protein plus methicillin. Kidney proteins might be carriers of bac¬ 
terial hapten, thus initiating an immune response to normal kidney tissue 
following infection. 
Finally, infectious damage to tubules need not be the only mechanism 
leading to an immune reaction in the kidney. Any insult to the tubules 
(including toxins, obstruction or ischemia) might lead to release of 
immunogenic proteins and might initiate immunologically mediated renal 
disease. 
McCluskey and Colvin (32) in their review of immunological aspects 
of renal tubular and interstitial disease suggest a mechanism by which 
patients with GN might have elevated titers of anti-kidney antibody. 
Many types of GN including membranoproliferative GN and rapidly progressive 
GN have associated tubulointerstitial deposits of immunoglobulin (33). 
Possibly the glomerular disease damages the tubule leading to release of 
antigen, and an immune response. 
The role of THP in pathogenesis of renal disease is not definitively 
determined, yet it need not be actively involved in the pathological pro¬ 
cess to be valuable as a serological marker of active renal pathology. 
Heparin 
Results obtained from patients at Yale-New Haven Hospital and the 
West Haven Veterans Administration Hospital indicate that heparin inhibits 
the measurement of anti-THP antibody. These results also showed a sig¬ 
nificant difference between anti-THP measured in heparinized and non- 
heparinized samples from the same person with decreased activity in hepar¬ 
inized samples. Adding heparin directly to serum demonstrates that heparin 
does not directly interfer with antigen-antibody binding, but must act 
through some substance present in plasma but not present in serum, such 
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as fibrinogen or heparin activated anti-thrombin III. Heparin exists as 
a heterogenous assortment of polymeric chains, and each chain length may 
have different physiological characteristics (34). It prevents coagulation 
of blood by binding to and activating anti-thrombin III, which then binds 
to and inhibits certain activated factors of the coagulation cascade 
(XIa (33), IXa (36), Xa (37), and thrombin (38)). 
One other possible source of interference with the RIA is fibrinogen. 
It might interfer by non-specifically binding to the solid phase antigen 
or to the added antibody, leading to a decrease in anti-THP titers. 
The further experiments with anti-coagulants including EDTA and sodium 
citrate, show that the inhibition initially observed in heparinized blood 
also appears in blood anti-coagulated with EDTA and citrate. Levels of 
antibody (in cpm) in specimens prepared with these two chelators of calcium, 
return to near control values after defibrinization with CaCl^. These 
results suggest fibrinogen as the serum protein which intergers with the RIA. 
The results presented here show that nearly all patients with end- 
stage kidney disease on dialysis do not have elevated titers of antibody 
when compared to normal controls. Larger study groups may be necessary 
in order to determine whether significant differences exist. 
Dialysis patients with end-stage kidney disease probably do not have 
an active pathological process in their kidneys. The normal anti-THP 
antibody titers in the patients studied here are the expected results, 
which reflects a return to normal levels of antibody if the hypothesis of 
THP mediated disease is correct. Future study of patients with active 
kidney disease, especially IN and CPN, may shed more light on the pathogenic 
role of THP in these diseases and may define more clearly the meaning of 
elevated anti-THP antibody titers already observed in certain patients (11,12). 
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During the course of the present study, it was noted that antibody 
titers measured by radioimmunoassay were lower in heparinized as compared 
with non-heparinized blood. The decrease in antibody titer was related 
to interference in the assay by fibrinogen rather than to any specific 
effect heparin might have on antigen-antibody interactions. 
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TABLE 1 
-I 
Clinical Data and Levels of Antibody to Taram-Horsfall 
Protein (Pre- and Post- Dialysis Expressed in CPM) 
in 45 Patients with End-Stage Kidney Disease 
Patient No. Pre- Post- Mos. on 
ng/ml 
(Age, Sex) cpm cpm A% Urine Dialysis 
PCKD - YNHH 
1 (63, F) 2150 2650 +23 Enterobacter 39 477 
2 (54, M) 2070 2820 +26 n.g. 34 455 
3 (60, M) 2770 3090 +11 anuric 48 655 
4 (49, M) 2920 3040 +4 anuric 29 700 
5 (64, F) 3030 2460 -19 anuric 31 733 
6 (60, F) 2390 2830 +19 anuric 48 544 
7 (65, F) 5720 4380 -24 diptheroids 47 1625 
8 (42, M) 3080 1850 -40 anuric 22 748 
9 (36, F) 3890 3280 -16 diptheroids 14 1002 
10 (20, M) 2260 3020 +33 anuric 37 508 
WHVAH 
11 (59, M) 2390 2120 -11 E. coli 12 544 
12 (52, M) 4030 3300 -18 anuric 106 1048 
13 (58, M) 1630 2270 +39 anuric 60 337 
n=13 x=2950 
s=1080 
x=2837 
s=642 
x=721 
s=341 
DN - YNHH 
14 (60, F) 12500 9730 -22 anuric 31 4329 
15 (37, M) 3930 3250 -17 n.g. 40 1015 
16 (71, F) 4400 4330 -2 E. coli 38 1170 
17 (49, F) 4210 3540 -16 anuric 10 1107 
18 (59, F) 3010 2890 -4 anuric 96 727 
19 (57, F) 1950 1650 -15 anuric 43 422 
20 (49, F) 3330 4400 +32 anuric 19 825 
WHVAH 
21 (64, M) 5140 5330 +4 anuric 119 1421 
22 (61, M) 3670 4174 +14 diptheroids 6 932 
n=9 x=4683 
s=3068 
x=4370 
s=2270 
x=1328 
GN - YNHH 
23 (28, M) 14318 10040 -30 anuric 26 5132 
24 (28, M) 3930 3310 +26 n.g. 9 1015 
25 (32, M) 4030 3900 -3 anuric 117 1048 
26 (26, M) 2460 4650 +90 anuric 59 565 
27 (24, F) 3250 3620 +11 anuric 67 800 
28 (35, F) 5360 5470 +2 anuric 56 1498 
29 (47, M) 2890 1810 -37 n.g. 25 691 
30 (19, F) 12750 11000 -14 E. coli 3 4437 
21- 

TABLE 1 
Continued 
GN - WHVAH 
31 (59, M) 1810 2640 +45 S. aureus 7 384 
32 (57, M) 1900 1410 -26 n.g. 1 408 
33 (54, M) 4400 3690 -16 anuric 60 1170 
34 (55, M) 1860 1750 -6 n.g. 64 398 
35 (53, M) 3930 4460 +13 anuric 96 1015 
36 (43, M) 1550 1350 -13 n.g. 88 316 
n=l4 x=4015 
s=4470 
x=4170 
s=2980 
x-1348 
CPN - YNHH 
37 (59, M) 6020 5820 -3 n.g. 42 1733 
38 (41, M) 5710 5350 -6 n.g. 49 1622 
39 (34, M) 4190 3800 -10 anuric 48 1100 
n=3 x=5300 
s=976 
x=4990 
s=1060 
x=1485 
IN - YNHH 
40 (43, M) 6870 5390 -22 anuric 31 2045 
41 (59, M) 5880 4300 -27 n.g. 77 1682 
WHVAH 
42 (50, M) 4020 5000 -24 Enterococcus 124 1045 
n=3 x=5590 
s=1450 
x=4900 
s-552 
x-1591 
MM - YNHH 
43 (49, M) 1740 1000 -43 n.g. 21 366 
WHVAH 
44 (51, M) 1540 1220 -21 Klebsiella 24 314 
n=2 x=1640 x-1110 x=340 
UTO - YNHH 
45 (21, M) 4170 3730 -11 Proteus 20 
n=45 
-22- 

TABLE II 
Levels of Antibody to Tamm-Horsfall Protein (expressed in CPM) 
in Heparinized and Non-heparinized Samples Collected from Volunteers 
Sample Non-heparinized Heparinized % 
KB 5140 3270 -36 
GC 4340 4290 -1 
BF 2800 2490 -11 
ML 11,090 6430 -42 
BS 5320 4730 -11 
JW 5180 4930 -5 
DB 9970 7400 -25 
JB 16,310 12,280 -25 
JK 6510 3980 -39 
BS 8660 6030 -30 
o
 
i—1
 
ii
 x=7530 x=5590 
sd=4040 sd=2780 
-23- 

TABLE III 
Effect of Coagulation Factors on Levels of Antibody to 
Tamm-Horsfall Protein (expressed in CPM) measured by this assay 
Sample CO Cl ED HE CO+Ca Cl+Ca ED+Ca HE+Ca 
AM 3570 2500 2280 2230 2380 2100 2340 1860 
SD 2630 2230 2610 2400 2950 2135 2890 2120 
TM 2710 2334 2400 2250 3150 2820 3070 2590 
BC 3620 2590 2820 3090 3200 3190 3170 2820 
RD 1830 1430 1510 1780 2130 1970 1990 1560 
JS 2950 2300 2330 2660 3020 2560 2680 2410 
SD 5120 3570 4300 3770 3770 3370 4130 4070 
JW 3180 2060 2380 3090 3290 3360 4050 3070 
SS 6290 4070 5310 4180 5200 4530 6480 5310 
DB 7020 4040 4560 4230 5390 5410 4270 4120 
n=10 x=3890 x=2720 x=3050 x=2970 x=3450 x=3140 x=3510 x=2990 
sd=1690 sd=894 sd=1230 sd=860 sd-1080 sd=1110 sd=1300 sd=1180 
CO=control, CI=sodium citrate, ED=EDTA, HE=heparin, Ca=calcium chloride 
x=mean, sd=standard deviation 
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FIGURE 1: Measurement of antibody to Tamm-Horsfall Protein (THP) in 
cpm and ng/ml in sera from patients with various types 
of end-stage kidney disease and control subjects. Bar 
graphs represent one standard deviation. PCKD = poly¬ 
cystic kidney disease, DN = diabetic nephropathy, GN = 
glomerulonephritis, CPN = chronic pyelonephritis, IN = 
interstitial nephritis, MM = multiple myeloma, UTO = 
urinary tract obstruction. 
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FIGURE 2: Measurement of antibody to Tamm-Horsfall Protein (THP) in 
cpm and ng/ml in sera from patients with end-stage 
kidney disease who have significant bacterial counts 
in their urine ( 10*> organisms per cc) of E. coli; other 
organisms including Enterobacter, Enterococcus, and 
diphtheroids; patients with sterile urine; patients 
who are anuric; and for comparison, non-infected controls. 
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FIGURE 3 Measurement of antibody to Tamm-Horsfall Protein (THP) in 
sera from patients with end-stage kidney disease , repre¬ 
sented as a function of number of months on dialysis. 
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FIGURE A Measurement of antibody to 
sera from patients with 
represented as a function 
Tamm-Horsfall Protein (THP) in 
polycystic kidney disease (PCKD) 
of number of months on dialysis. 
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FIGURE 5 Measurement of antibody to 
sera from patients with 
as a function of number o 
Tamm-Horsfall Protein (THP) in 
diabetic nephropathy (DN) expresse 
f months on dialysis. 
d 
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FIGURE 6 Measurement of antibody to Tamm-Horsfall Prote 
sera from patients with glomerulonephritis 
sented as a function of number of months on 
in (THP) in 
(GN) repre¬ 
dialysis . 
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FIGURE 7 Measurement of 
sera from pat 
interstitial 
of number of 
antibody to Tamm-Horsfall Protein (THP) in 
ients with chronic Phelonephritis (CPN) and 
nephritis (IN) represented as a function 
months on dialysis. 
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_8: Measurement of antibody to Tamm-Horsfall Protein (THP) in 
non-heparinized and heparinized samples obtained from 
volunteers. Titers expressed in cpm. Bar graphs represent 
one standard deviation. 
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FICL'RE 9: Measurement of antibody to Tamm-Horsfall Protein (THP) in 
immune rabbit serum to which heparin was added to make 
final concentrations equal to, 5x, lOx, 50x, and lOOx 
the concentration of heparin in patients at completion of 
dialysis. 
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